Search results
White Hut Holyoke invites patrons to support baby’s recovery from acute myeloid leukemia
The Republican· 5 days agoAshton Conroy, the son of Holyoke Police Officer Crystal Conroy, is courageously battling acute ...
GlycoMimetics reports Phase 3 trial of uproleselan falls short By Investing.com
Investing.com· 17 hours agoThe study aimed to determine the efficacy of uproleselan in improving survival rates when used...
Earnings call: Kura Oncology reports on ziftomenib's progress By Investing.com
Investing.com· 18 hours agoZiftomenib has received Breakthrough Therapy designation from the FDA for the treatment of...
CD7 expression tied to poorer outcomes with newly diagnosed leukemia
Medical Xpress· 3 days agoCD7 expression is associated with poorer outcomes in patients with newly diagnosed acute myeloid ...
New approach for developing cancer vaccines could make immunotherapies more effective in acute ...
Medical Xpress· 4 days agoIn a new study published in Blood Advances, researchers from the UChicago Pritzker School of...
...for Treatment of Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia/Myelodysplastic...
CBS 47 Fresno· 5 days agoAdditionally, the company also announced that REM-422 has received Orphan Drug Designation from the FDA for the treatment of ACC and AML...
TC BioPharm Announces Exercise of Warrants for £3.1 Million Gross Proceeds
Morningstar· 18 hours agoTC BioPharm (Holdings) plc ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today ...
GlycoMimetics fails phase 3 blood cancer trial, causing investors to sour on stock
FierceBiotech· 23 hours agoMonday, GlycoMimetics reported the failure of the trial—spurring a 72% stock drop that crushed the company's share price to 51 cents in premarket trading Monday morning, compared to $1.83 at ...
Why Is GlycoMimetics (GLYC) Stock Down 77% Today?
InvestorPlace· 23 hours agoGlycoMimetics (NASDAQ:GLYC) stock is taking a beating on Monday after the biotechnology company announced results from a Phase 3 clinical trial....
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on...
Digital Journal· 15 hours agoThe Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib, an oral, kinase inhibitor that has demonstrated activity as a monotherapy ...